A number of firms have modified their ratings and price targets on shares of Evotec AG (NASDAQ: EVTCY) recently:

  • 9/1/2017 – Evotec AG was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $43.00 price target on the stock. According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “
  • 8/30/2017 – Evotec AG was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “
  • 8/25/2017 – Evotec AG was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $42.00 price target on the stock. According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “
  • 8/24/2017 – Evotec AG was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “
  • 8/17/2017 – Evotec AG had its “sell” rating reaffirmed by analysts at DZ Bank AG.
  • 8/10/2017 – Evotec AG had its “sell” rating reaffirmed by analysts at DZ Bank AG.
  • 7/31/2017 – Evotec AG had its “sell” rating reaffirmed by analysts at DZ Bank AG.
  • 7/12/2017 – Evotec AG had its “sell” rating reaffirmed by analysts at DZ Bank AG.

Evotec AG (NASDAQ EVTCY) remained flat at $41.34 during trading on Thursday. 1 shares of the stock were exchanged. The company’s 50 day moving average is $33.23 and its 200-day moving average is $26.64. The stock has a market capitalization of $3.03 billion and a price-to-earnings ratio of 71.03. Evotec AG has a 1-year low of $9.79 and a 1-year high of $41.69.

Evotec AG (NASDAQ:EVTCY) last announced its quarterly earnings data on Thursday, August 10th. The company reported $0.04 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The firm had revenue of $58.52 million for the quarter, compared to analysts’ expectations of $50.06 million.

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.